11:21 AM EDT, 10/30/2024 (MT Newswires) -- Scilex ( SCLX ) said Wednesday it has concluded its phase 2 meeting with the US Food and Drug Administration regarding its product candidate SP-103, which is intended for treating neck pain with muscle spasms.

The FDA outlined a clear pathway to a new drug application following the completion of phase 3 trials, the company said.

Shares of Scilex ( SCLX ) were up 1.5% in recent Wednesday trading.

Price: 1.01, Change: +0.02, Percent Change: +1.51